Table 1 Demographics of participants
DN-NMOSD (n = 17) | AQP4–NMOSD (n = 30) | MOGAD (n = 17) | ONDs (n = 15) | |
|---|---|---|---|---|
Age at sampling (years, mean ± SD) | 32.3 ± 9.6 | 35.2 ± 11.1 | 31.2 ± 7.3 | 36.8 ± 7.4 |
Gender (female:male) | 10:7 | 27:3 | 13:4 | 8:7 |
Ethnicity | Korean (11), Thai (1), Caucasian (4), Turkish (1) | Korean (29), Thai (1) | Korean (17) | Korean (15) |
Phenotypes met the seronegative NMOSD criteria | ||||
ON + LETM ON + cerebral ON + APS ON + brainstem LETM + brainstem LETM + cerebral Brainstem + cerebral | 6 4 1 0 4 1 1 | NA | 4/10 1/10 0/10 3/10 0/10 1/10 1/10 | NA |
Attack type at sampling | M (7), B (4), ON (5), Multiple (1) | M (14), B (7), ON (8), Multiple (1) | M (6), B(6), ON (4), Multiple (1) | NA |
Presence of maintenance immunosuppressive therapy at sampling | 6/17 (35.3%) | 14/30 (46.7%) | 3/17 (17.6%) | NA |
Azathioprine | 4 | 2 | 2 | |
Mycophenolate | 0 | 6 | 0 | |
Rituximab | 1 | 5 | 1 | |
Cyclophosphamide | 1 | 0 | 0 | |
Methotrexate | 0 | 1 | 0 | |